Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | HPGD | P15428 | 4/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TLR4 | O00206 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pulegone SCHEMBL38305 | 1.00 | PTPN2 (0.35) | PTPN2PTPN1ALDH1A1HPGDHTT | |
| Pulegone SCHEMBL58181 | 1.00 | PTPN2 (0.35) | PTPN2PTPN1ALDH1A1HPGDHTT | |
| Pulegone SCHEMBL8836781 | 0.98 | ALDH1A1 (0.34) | PTPN2PTPN1ALDH1A1HPGDHTT | |
| Pulegone SCHEMBL9292430 | 0.98 | PTPN2 (0.38) | PTPN2PTPN1ALDH1A1HPGDHTT | |
| Pulegone SCHEMBL8836768 | 0.98 | ALDH1A1 (0.34) | PTPN2PTPN1ALDH1A1HPGDHTT | |
| Pulegone SCHEMBL23752046 | 0.98 | ALDH1A1 (0.34) | PTPN2PTPN1ALDH1A1HPGDHTT | |
| Pulegone SCHEMBL8196865 | 0.88 | CYP1A2 (0.36) | PTPN1ALDH1A1HPGDKDM4ENPC1 | |
| Pulegone SCHEMBL6517913 | 0.86 | — | — | |
| Pulegone SCHEMBL17963980 | 0.82 | TLR4 (0.31) | TLR4NPC1 | |
| Pulegone SCHEMBL17064214 | 0.82 | TLR4 (0.31) | TLR4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025090945-A1 | FORMULATIONS HAVING A GLYCOSIDE AND A LIPOPHILIC COMPONENT | SPOKE SCIENCES, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| EP-4440556-A2 | PARTICLES, AQUEOUS DISPERSIONS, AND LIQUID COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | Spoke Sciences, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240285549-A1 | CANNABIS OIL COMPOSITIONS AND METHODS FOR PREPARATION THEREOF | CONSTANCE THERAPEUTICS, INC. (US) | 2024-08-29 | — | — | US | disclosed |
| EP-4402126-A1 | AHR AGONISTS | Eli Lilly and Company (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20240216456-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240216457-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240207344-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207343-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207342-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-06-27 | — | — | US | disclosed |
| CN-118215654-A | AHR agonists | 伊莱利利公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-101612360-B | Medicine for treating hepatitis, hepatocirrhosis and liver cancer | JIAHUI XIAO | 2010-07-21 | — | — | CN | disclosed |
| US-20100167036-A1 | SOLID POLYMERIC MATERIALS FOR DETECTION, TRANSFER, AMPLIFICATION AND MEMORY OF CHIRALITY OF OPTICALLY ACTIVE COMPOUNDS | UNIVERSITA DEGLI STUDI DI (IT) | 2010-07-01 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
| CN-101612360-A | The medicine of treatment hepatitis, liver cirrhosis, hepatocarcinoma | JIAHUI XIAO | 2009-12-30 | — | — | CN | disclosed |
| CN-101208082-A | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK & CO INC (US) | 2008-06-25 | — | — | CN | disclosed |
| WO-2007002557-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060160719-A1 | Flavor and fragrance compositions | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-07-20 | — | — | US | disclosed |
| US-6190685-B1 | FOR TREATING IMMUNE DISEASES SUCH AS ACQUIRED IMMUNE DIFICIENCY SYNDROME(AIDS) | TAKAHISA KARITA (JP) | 2001-02-20 | — | — | US | disclosed |
| CN-1275914-A | Antioxidizing composition for scavenging free radicals, pharmaceutical composition comprising the same, and process for preparing the same | KARITA TAKESHI (JP) | 2000-12-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285549-A1 | CANNABIS OIL COMPOSITIONS AND METHODS FOR PREPARATION THEREOF | CNR1, CNR2, PROC | PTPN2 4162/4885PTPN1 4090/4885ALDH1A1 1486/4885 |
| US-20060160719-A1 | Flavor and fragrance compositions | TAS2R8, TAS2R5, TAS2R7 | PTPN2 4465/4885PTPN1 3903/4885ALDH1A1 136/4885 |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | PTPN2 3619/4885PTPN1 3464/4885ALDH1A1 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.